In the last trading session, 1.02 million Iterum Therapeutics Plc (NASDAQ:ITRM) shares changed hands as the company’s beta touched 1.90. With the company’s per share price at $1.61 changed hands at $0.43 or 36.44% during last session, the market valuation stood at $21.01M. ITRM’s last price was a premium, traded about 4.35% off its 52-week high of $1.54. The share price had its 52-week low at $0.60, which suggests the last value was 62.73% up since then. When we look at Iterum Therapeutics Plc’s average trading volume, we note the 10-day average is 0.23 million shares, with the 3-month average coming to 44.02K.
Analysts gave the Iterum Therapeutics Plc (ITRM) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ITRM as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Iterum Therapeutics Plc’s EPS for the current quarter is expected to be -$0.9.
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Instantly ITRM was in green as seen at the end of in last trading. With action 103.80%, the performance over the past five days has been green. The jump to weekly highs of 1.8000 on Friday, 11/17/23 added 36.44% to the stock’s daily price. The company’s shares are showing year-to-date upside of 91.67%, with the 5-day performance at 103.80% in the green. However, in the 30-day time frame, Iterum Therapeutics Plc (NASDAQ:ITRM) is 139.94% up. Looking at the short shares, we see there were 48900.0 shares sold at short interest cover period of 1.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is $15.00, meaning bulls need an upside of 89.27% from its current market value. According to analyst projections, ITRM’s forecast low is $15.00 with $15.00 as the target high. To hit the forecast high, the stock’s price needs a -831.68% plunge from its current level, while the stock would need to soar -831.68% for it to hit the projected low.
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Data shows that the Iterum Therapeutics Plc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 41.13% over the past 6 months, a 2.48% in annual growth rate that is considerably lower than the industry average of 11.30%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Iterum Therapeutics Plc will fall -200.00%, while the growth in revenue is estimated to hit -46.70% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.51%. The 2023 estimates are for Iterum Therapeutics Plc earnings to decrease by -48.92%.
Iterum Therapeutics Plc is expected to release its next quarterly earnings report on November 14.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.25% of Iterum Therapeutics Plc shares while 1.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 1.30%. There are 1.28% institutions holding the Iterum Therapeutics Plc stock share, with Apollon Wealth Management, LLC the top institutional holder. As of Jun 29, 2023, the company held 1.53% of the shares, roughly 0.2 million ITRM shares worth $0.21 million.
New Leaf Venture Partners, L.L.C. holds the second largest percentage of outstanding shares, with 0.74% or 97084.0 shares worth $0.1 million as of Jun 29, 2023.
With 6139.0 shares estimated at $7059.0 under it, the former controlled 0.05% of total outstanding shares.